DERMATITIS, ATOPIC

This long-term study is testing the safety and effectiveness of amlitelimab, an injected drug, in over 1600 people with moderate to severe atopic dermatitis (eczema) who have already taken part in earlier amlitelimab trials. Some participants will stop treatment temporarily to se…

This study follows 262 people with moderate-to-severe atopic dermatitis (eczema) who received an injection of FURESTEM-AD in an earlier trial. Researchers are checking for long-term side effects and tracking how well the treatment controls eczema symptoms over time. The goal is t…

This study is testing the long-term safety and effectiveness of a drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive injections of amlitelimab for up to 5 years, and researchers monitor for side effects an…

This study tests the drug lebrikizumab in 520 adults and teens (ages 12+) with moderate-to-severe eczema. Part 1 looks at how well the drug improves skin symptoms over 24 weeks. Part 2 compares a new dosing schedule (every 12 weeks) to the current one (every 4 weeks) to see if it…

This study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue the drug or receive a p…

This study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dup…

This study tests a new drug called BAT6026 in 33 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The drug is a monoclonal antibody given as an injection. The goal is to see if it is safe and can reduce eczema severity by…

This study was designed to see how well JAK inhibitors work for adults with moderate-to-severe eczema in real-world settings. It planned to track skin improvement, itching, sleep, and side effects. However, the study was withdrawn before enrolling any participants, so no results …

This study follows 858 people aged 12 and older with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers will collect information on their medical history, skin symptoms, and quality of life over time to see how the medicine works in everyday practice…